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Background: The purpose of this retrospective follow-up study is to evaluate the prevalence of patients with
thyroid eye disease presenting with apparent unilateral proptosis and determine the occurrence of exophthalmos
in contralateral non-proptotic eye over the time. Associated features with this event were evaluated.
Methods: A cohort of 655 consecutive patients affected by thyroid eye disease with a minimum follow-up of 10
years was reviewed. Exophthalmos was assessed by using both Hertel exophthalmometer and computed
tomography (CT). The influence of age, gender, hormonal status and of different therapies such as corticosteroids,
radiotherapy and surgical decompression on this disease progression was evaluated.
Results: A total of 89 patients (13.5%) (95% confidence interval [CI] 15%-10%) had clinical evidence of unilateral
exophthalmos at the first visit. Among these, 13 patients (14%) (95% CI 22%-7%) developed subsequent
contralateral exophthalmos. The increase of protrusion ranged from 2 to 7 mm (mean of 4.2). The time of onset
varied from 6 months to 7 years (mean time: 29 months). Smoking status, young age and surgical decompression
are significantly associated with development of contralateral proptosis (p< .05).
Conclusions: Asymmetric thyroid eye disease with the appearance of unilateral exophthalmos at the initial
examination is a fairly frequent event, while subsequent contralateral proptosis occurs less commonly. However,
physicians should be aware that young patients, particularly if smokers, undergoing orbital decompression in one
eye may need further surgery on contralateral side over time.
Keywords: Thyroid eye disease, Unilateral proptosis, ExophthalmosBackground
Thyroid Eye Disease (TED) is the most frequent
extrathyroidal manifestation of Graves’ disease [1], and
results from an increased volume of orbital tissues (con-
nective and adipose tissue, interstitial enlargement of
extraocular muscles) within the enclosed space of the
bony orbits [2]. Although excellent review articles have
been published on TED [1,3-5], it remains a pathogenetic
enigma and a therapeutic dilemma. Once initiated, the
orbital immune process frequently assumes a momentum* Correspondence: strianes@unina.it
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reproduction in any medium, provided the orof its own, leading to non-specific but nonetheless harm-
ful consequences such as tissue hypoxia, oxygen free rad-
ical damage, and fibrogenic tissue remodeling [6].
Thyroid Eye Disease is a self-limiting disease with ac-
tive and static phases. The initial active inflammatory
phase usually lasts for 6–24 months, but may sometimes
continue for several years [2,7,8].
Exophthalmos, probably the most widely known symp-
tom of TED, occurs in 20–30% of patients with Graves’
disease and up to 40–70% of patients with TED [9]. In
the majority of patients both eyes are equally affected, al-
though often in an asymmetric manner [10]. Pure unilat-
eral ophthalmopathy is rare, with 5% to 11% of cases
showing no progression to bilateral disease [11]. However,al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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probably patients presenting with very asymmetric TED
show subclinical disease in the less affected orbit. Radio-
logical findings can often be demonstrated in the fellow
eye and clinical evidence of TED may become clear during
the course of the disease [8]. The natural history of unilat-
eral TED is unknown and the diagnosis remains challen-
ging [12]. This study aims to assess the patients who were
referred to a tertiary orbital clinic with TED with the
appearance of unilateral proptosis, and how many in
this group went on to develop subsequent contralateral
involvement. The influence of age, gender, hormonal status
and of different therapies such as corticosteroids, radio-
therapy and surgical decompression on this phenomenon
is evaluated.
Given that TED is a disfiguring and disabling disease
that influences and impairs the quality of life of affected
individuals [3], when contralateral proptosis occurs, the
need for further therapy is a frustrating event for the pa-
tient. To our knowledge, there are no specific reports in
the literature on this phenomenon, and its incidence and
characteristics are poorly documented.
Methods
A cohort of 655 consecutive patients with TED who vis-
ited and were managed at the Orbital Unit of the De-
partment of Visual Science of the University of Naples
“Federico II” from January 1995 to December 2009, were
retrospectively reviewed. The aim was to determine the
percentage of patients presenting with unilateral TED
with the appearance of unilateral exophthalmos and who
had previous clinical history with no remarkable changes
in their appearance and to evaluate the percentage of pa-
tients who developed over time exophthalmos on
contralateral non-proptotic eye. To ensure a reasonable
time period that produces suitable data for statistical
analysis, the minimum follow-up time for the patients
was 10 years. Data was extracted from a special TED
form which is routinely completed for each patient in
our Orbital Unit. The study adheres to the declaration
of Helsinki. The form included different sections regard-
ing age, sex, thyroid gland disorder, associated systemic
diseases, medication history, and eye symptoms at presen-
tation of TED. It also included a section for visual function
tests including best corrected visual acuity, optic disc,
color vision, visual field, intraocular pressure (IOP) in pri-
mary and up-gaze, Hertel exophthalmometry, eyelid
examination, ocular motility examination [13], slit-lamp
examination and findings on orbital imaging. The examin-
ation included a clinical activity score (CAS) and a
NOSPECS severity score [14]. In the case of asymmetric
severity and/or activity scores, the worst score was consid-
ered for statistical analysis. To help enhance the accuracy
of data collection, the charts of patients with morecomplicated medical courses were independently ab-
stracted by senior a ophthalmologist who is experienced
in the care of patients with TED (DS, RP, GB), and by an
ophtlhalmologist-in-training (CC, PG, IB).
Clinical measurement of the exophthalmos is performed
in our clinic by using "Hertel" Oculus exophthalmometer,
and followed by using a similar intercanthal width for each
individual patient. Two observers routinely perform read-
ings: usually one fellow or resident and one senior (DS,
RP, GB). An asymmetric proptosis was considered signifi-
cant if the difference between eyes was > 2 mm [7], and
when measurement of the non-proptotic eye produced a
result of < 16 mm for female and <20 mm for males
according to the previous study on Caucasian population
performed by Mourits [15].
For the study purposes the exophthalmos was quantified
by reviewing the CT scan. All patients referred to our
clinic presenting with exophthalmos routinely undergo
CT evaluation to exclude the presence of other causes of
proptosis and to assess the follow-up [16,17]. In this co-
hort, 353 patients (54%) were evaluated with a CT scan
(Marconi MX 8000, Philips Medical System) performed at
the Radiology Department of the University of Naples
“Federico II”. Standard axial, 1.33-mm-thick, spiral CT
images (increment 0.6mm, pitch 0.875 mm, mAS/slice
200, KV 120) were obtained. Following acquisition, the
scans were post-processed with multiplanar reconstruc-
tions (MPR) on the coronal plane. The window settings
were adjusted to better visualize the single structures
(muscles, globe, nerves, and fat). Upon admission, 302 pa-
tients (46%) produced a CT exam which had been previ-
ously conducted at another medical center; the exams
were deemed appropriate for this study if performed with
1.33-mm-thick acquisition. The authors (AE, MN) had
post-processed the DICOM files images with multiplanar
reconstructions (MPR) on the coronal and sagittal plane.
Results of the examinations were scored by the same
observer (AE, MN) in a blinded manner and initial and
long-term follow-up CT examinations were digitally
combined and compared to determine variations of the
following parameters: side of involvement (L/R); number
of involved EOMs; most severely affected EOM; degree
of exophthalmos; apical crowding (Y/N); optic nerve
(ON) rectitude (Y/N); superior ophthalmic vein (SOV) en-
largement (Y/N); orbital lipomatosis and adipose involu-
tion of EOMs (Y/N). The lengths of the interzygomatic
line and globe position were measured on axial scans of
the mid-globe section. The number and dimension of the
involved EOMs were evaluated on CT coronal images
[18,19]. Volumetric analysis was eventually performed.
To determine the position of the globe and the grade of
the exophthalmos, on CT, the perpendicular distance
between the interzygomatic line and the posterior margin
of the globe at the mid-globe section (where the middle
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axial scan.
Medical and/or surgical treatments administered for
the initial proptosis were carefully analyzed to study
their influence on the outcome. Thyroid function- status
was based on standard test.
To evaluate the influence of age, gender, hormonal and
smoker status and of different therapies such as corticoste-
roids, radiotherapy and surgical decompression on this
phenomenon on the development of contralateral prop-
tosis, we compared statistically the group of patients who
remained with asymmetric proptosis (group 1) with those
who showed contralateral proptosis over time (group 2).
Univariate analysis was used to evaluate correlations
between clinical factors (sex, age, surgery, corticosteroid
therapy, radiotherapy, thyroid hormonal status) and the
incidence of controlateral disease. Dichotomic variables
were tested by Pearson Chi-square test, Fischer exact
test or Students’T test when appropriate. The median
and the range were used to describe all continuous vari-
ables and nonparametric techniques were used for ana-
lyzing them (Mann–Whitney U test). To evaluate the
risk associated with the presence of a significant clinical
factors the Cox regression analysis was adopted. All stat-
istical tests were two-sided, and a p value of 0.05 was
considered statistically significant. Statistical analysis was
performed with SPSS 18.0 statistical software (SPSS Inc.,
Chicago, IL).
Results
Of the 655 patients enrolled in this study, 89 (13.5%) (95%
confidence interval [CI] 15%-10%) presented with unilat-
eral exophthalmos. Exophthalmometer values in the
proptotic eye ranged from 17 to 29 mm, with a median
value of 25.2. There were 31 (35%) men and 58 (65%)
women. CAS values ranged from 3 to 6 with a mean value
of 4.1 in the proptotic eye and from 2 to 4 with a mean of
2.8 in the fellow eye. No significant relation was found be-
tween the CAS at the initial visit and the development of
proptosis (worst score was considered for the analysis in
asymmetric cases). Twenty-four (27%) patients had con-
comitant eye movement restriction in the proptotic eye;
none had extraocular muscle impairment in the un-
affected eye. Among the 89 patients with asymmetric
proptosis, 13 patients (14%) (95% CI 22%-7%) (7 women
and 6 males) developed contralateral exophthalmos during
the 10-years of follow-up. In all cases, the increase in
Hertel exophthalmometry measurements was > 2 mm,
and ranged from 2 to 5 mm (median of 3.2). Review of the
CT scan confirmed this data and differences were not sta-
tistically significant. The contralateral exophthalmos
developed over a length of time, which varied from a mini-
mum of 6 months to a maximum of 7 years, with a me-
dian time of 29 months. In particular, contralateralproptosis developed in 3 (23.%) patients within 36 months
from the onset (3±0.9-mean CAS ± standard deviation), in
4 patients (30%) between 3 to 5 years (4.41±1.3 mean
CAS ± standard deviation), and in 5 patients (37%) at a
time >5 years (5±0.786 mean CAS ± standard deviation).
Volumetric analysis of proptotic eye on CT performed
at the time of initial presentation showed in proptotic
eyes: enlargement of both the orbital fat compartment
and the extraocular muscles in 56 patients (63%), in-
volvement of only adipose tissue in 14 patients (16%) and
increased enlargement of only extraocular muscle (mean
sizes: inferior rectus 6.5 mm, superior rectus 5.8 mm,
medial rectus 4.6 mm, and lateral rectus 5.1 mm) in 19
patients (21%) whereas in non-proptotic eyes: absent in
56 patients (63%) or minimal increase (37%) of the fat
compartment with muscles of normal size (79%) or mini-
mum enlargement of one muscle (21%) (mean size: infer-
ior rectus 4.3 mm, superior rectus 5.0 mm, medial rectus
4.0 mm, and lateral rectus 3.6 mm); these features were
consistent with the condition of asymmetric proptosis
(Figure 1).
Imaging at the time of development of contralateral
exophthalmos revealed increases in both the individual
and total sizes of the extraocular muscles (mean size:
inferior rectus 6.3 mm, superior rectus 5.9 mm, medial
rectus 4.8 mm, and lateral rectus 5.0 mm) using the pre-
viously described criteria [20]. Distribution of the pa-
tients in the 2 groups was as follows: group 1, 76 patients
and group 2, 13 patients. Patients who developed contra-
lateral exophthalmos (group 2) were an average of 8.5
years younger than those patients who remained stable
(group 1) (p = 0.039).
More patients who showed unilateral proptosis were
smokers compared to those who were not (chi-square
test, p = 0.021).
Different therapies were administrated to the 2 groups.
Group 1: 40 patients (52.%) received corticosteroid pulse
therapy, 4 patients (5.%) received radiotherapy, and 22 pa-
tients (28.%) received orbital decompression. Group 2: 10
patients (76.%) received corticosteroid therapy, 8 patients
(61.%) received orbital decompression, and 1 patient (7.%)
received radiotherapy (Table 1). Among those different ther-
apies, only surgical decompression was related with a higher
incidence of contralateral proptosis (p< 0.02) and progres-
sion in the not operated eye followed from 6 months to 2
years period. It was reported in literature that TED has a
more aggressive course in males [21], however, we were
not able to demonstrate statistically the same figure.
No difference of hormonal status between the 2 groups
was found at the initial presentation.
Discussion
TED usually involves both orbits, although clinical signs
tend to manifest asymmetrically. When TED presents
Table 1 Comparison of demographic, clinical, biochemical
features and different therapies between the 2 groups of
patients
Comparative values among two groups
Group 1 Group 2
N°(%) N°(%) p Test
Sex
Male 25 (32.9) 6 (46.2) 0.54
Χ2
Female 51 (67.1) 7 (53.8)
Surgery
With decompression 22 (28.9) 8 (61.5) 0.05
Χ2
Without decompress. 54 (71.1) 5 (38.5)
Corticosteroid therapy
Performed 40 (52,6) 10 (76,9)
0.14 Fisher
Not done 36 (47,4) 3 (23,1)
Radiotherapy
Performed 4 (5.3) 1 (7.7)
0.55 Fisher
Not done 36 (47,4) 3 (23,1)
Initial thyroid hormone status
Euthyroid 4 (5.3) 1 (92.3)
0.55 Fisher
Hyperthyroidism 72 (94.7) 12 (7.7)
Median age 44 (19–71) 32 (24–58) 0.1 U
CAS (mean value+/− DS) 4.2±1.8 4±0.8 0,66 t
Smoker 17 (19.) 12 (50.0) 0.02 Χ2
Figure 1 Axial 1.3 mm CT scan of the orbit in soft-tissue windows. Unilateral exophthalmos is evaluated by the perpendicular distance
between the interzygomatic line and the posterior margin of the globe at the mid-globe sections.
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such as inflammation, impairment of eye motility and
eyelid retraction [22], may be present in the fellow eye,
and contralateral proptosis may become clear during the
course of the disease [9,12]. Literature on actual unilat-
eral TED is relatively scarce and heterogeneous and
there are no conclusive data and explanations for this
event. The number of patients having pure unilateral
TED reported to range from 9% to 15% [9,10,23]. In our
study, we found 13% of patients presenting unilateral
TED with the appearance of unilateral proptosis. Bartley
reported unilateral proptosis at the onset in 8,5% of pa-
tients in a cohort of cases with TED [24]. Kendler and
Rootman reported unilateral exophthalmos in 13% of pa-
tients from a series of 557 consecutive cases [21]. This
variation could be explained by the fact that in previous
studies, the evaluation of proptosis was based solely on
Hertel exophthalmometry, hence the different percent-
ages reported might be explained by an unavoidable
inter-observer variation when using this method [25,26].
Our study includes a review of CT imaging to more ac-
curately define the proptosis as being asymmetric, be-
cause some reports suggest that clinically unilateral
disease is bilateral from the onset [9,12]. It is also known
that a CT scan can demonstrate contralateral eye muscle
involvement in 50–90% of patients with clinical unilat-
eral eye involvement [18,23]. Given the systemic nature
of the disease, it seems far more likely that both orbits
were involved but to a very different extent. This is sup-
ported by the fact that CT imaging picked up some sign
of contralateral involvement in this study patients
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Hertel and CT imaging measurements, though within
the normal range, may be increased for an individual pa-
tient. More accurate testing, such as MR imaging, would
likely show a higher number of uninvolved orbits having
subtle changes, but we were unable to collect data on
MRI exam on all patients.
Published data concerning delayed development of
proptosis in the contralateral eye are very few. Kalmann
and Mourits have described one case of late recurrence
of unilateral TED on the contralateral side after 7 years
of follow-up [27].
We observed 13 patients who developed a subsequent
increase in exophthalmometry measurements in the
non-proptotic eye within a period ranging from 6
months to 7 years. We believe that such a variable range
of time for this occurrence suggests the presence of dif-
ferent pathological mechanisms. For those presenting
with proptosis within 36 months, unilateral TED prob-
ably represents an early stage of the disease-initially lim-
ited to only one eye, and the contralateral proptosis is due
to a prolonged manifestation of the disease, concealing its
activity due to the use of corticosteroids and radiotherapy
[9]. A high percentage of patients in both groups in our
study had been treated with a corticosteroid before pres-
entation, and it remains a challenge to explain factors
leading to a less rapid progression of TED in one eye ra-
ther than the fellow eye. Considering that the 78% patients
in group 2 needed corticosteroid versus the 53% of pa-
tients of group 1, it could be argued that patients who
progressed onto bilateral proptosis have worse disease in
general, and this could be suggested by a trend even in the
absence of statistically significant p value.
When proptosis occurred within a period between 3
and 5 years, which describes 40% of patients in our
study, it may be considered to be a result of subclinical,
slow progressing, chronic inflammation and (or) fibrosis.
We did not observe an actual increase of the CAS
(4.41±1.3) before the proptosis occurred.
We observed 3 patients who had contralateral prop-
tosis after >5 years, perhaps as a consequence of a late
reactivation of TED (CAS: 5±0.786). Late reactivation of
TED was also reported in 5% of patients having, with an
increase in "Hertel" exophthalmometry readings after 5
years of follow-up [11]. The authors suspected that this
was not due to a slow subclinical progression of disease
activity or to fibrosis prior to representation, but rather
due to a significant increase in activity at the time of re-
currence [11]. We observed an increase of CAS during
the 6 months prior to the presentation of proptosis; this
observation is consistent with this proposed mechanism.
The clinical course of TED is independent of thyroid
status and a temporal relation to thyroid disease is not
consistent [28], but TED tends to be more severe inpatients with poorly controlled hyperthyroidism and
those rendered hypothyroid [11]. TED may occur under
euthyroid conditions with no obvious precipitants and it
often presents as a reactivation of myopathy [11]. In our
cases, there was no significant difference in the initial
thyroid status when comparing the 2 groups of patients.
We considered only the thyroid status during the previ-
ous 6 months prior to development of the contralateral
proptosis, and hence we are unable to offer statistics
concerning the influence of different treatments used for
thyroid disorders and TED, which may in some way
affect the evolution of proptosis.
It is thought that individuals >50 years of age tend to
have worse ophthalmopathy than younger individuals
[23,28]. In our investigation, the risk for developing
contralateral proptosis was higher in younger patients
(average age of group 1 was 8.5 years less than age of
group 2).This finding correlates well with the results
reported by Rootman, who found that TED in young pa-
tients tends to be more asymmetric [21].
It is possible that the difference in average age between
the groups could be accounted for by younger patients
who tend to have a prolonged active phase (which would
be more likely to progress on either side), while older
patients came to our clinic in the post-inflammatory
phase.
It is well known that smoking also contributes signifi-
cantly to the severity and recurrence of TED [29,30]. In
our study smoking history was found to be related to
the development of contralateral proptosis, thus, it is
important for patients with Graves’ disease to refrain
from smoking.
Comparing the different therapies previously adminis-
trated (corticosteroids, radiotherapy, and surgical decom-
pression), only surgical decompression was associated
with a statistically significant occurrence of contralateral
exopthalmos. We believe that this result could be related
to the fact that TED is an autoimmune disease, and the re-
leasing and spreading of an immunogenic orbital inducer
during surgical decompression can serve as a trigger agent
in developing contralateral proptosis. Wai et al. described
a severe reactivation of TED, which occurred 3 weeks after
cataract surgery in a patient who had inactive ophthal-
mopathy for 24 years. The authors hypothesized that
trauma and pressure in the retrobulbar space induced by
retrobulbar anesthsia triggered local inflammatory and im-
mune responses, which in turn caused progression of
TED [31,32]. Recently a similiar mechanism was reported
to explain 3 cases of homolateral reactivation of the dis-
ease after orbital decompression [33]. Wenz et al. de-
scribed 3 patients who had orbital decompression for
compressive optic neuropathy and then subsequently re-
lapsed due to progressive extraocular muscle enlarge-
ment [34].
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steroids therapy, the low levels of p-value and power of
the statistic test (0.14, power <70%) could suggest a
trend of a worse disease in general for those patients
who developed contralateral proptosis, since they needed
corticosteroid in higher percentage.
Conclusions
Our data supports the view that the non-proptotic and
clinically less affected eye could be involved in TED dur-
ing the long-term follow-up. Thus, although the clinical
presentation of TED may often be asymmetric, it is be-
lieved to be truly unilateral in a minority of cases, as
would be expected in a systemic disease. We believe,
however, that all the hypotheses proposed to explain
unilateral TED in previous studies and in the present
one are still biased by the lack of a general consensus
concerning the measurement values used to determine
disease activity, progression, and severity. The main goal
of our study was to assess the unilateral TED with the
appearance of unilateral proptosis and to evaluate the
occurrence of subsequent contralateral proptosis. There-
fore this study would provide information necessary for
the management of patients affected by TED, since we
believe that the knowledge concerning the progression
of unilateral presentation of TED to bilateral might be
useful both for the physician when planning the therapy
and for the patients.
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